[Medical treatment of depression in children and adolescents].
Pharmacological treatment of depression in minors is contested after some published warnings about suicide related behaviour among youths treated with SSRI. This paper examines the last developments concerning antidepressant use in minors, prescrition patterns and evidence of antidepressants used in minors. Reviewing the guidelines and practise parameters, metaanalyses and the TADS-study a recommendation for an evidence based use in minors can only be given for Fluoxetine. Safety aspects should be taken into consideration during the treatment and patients should be kept in close contact to their therapists to observe suicidal related behaviour and adherence.
Kölch
Michael
M
Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie der Universität Ulm. michael.koelch@uniklinik-ulm.de
Fegert
Jörg M
JM
D000293:Adolescent; D016907:Adverse Drug Reaction Reporting Systems; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D019317:Evidence-Based Medicine; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000092864:Suicide Prevention
D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors